Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders
In 2012, Vertex Pharmaceutical s (NASDAQ: VRTX) earned approval for the first medicine that targeted the underlying causes of cystic fibrosis (CF), a rare disease that harms patients' lungs and pancreases. Since then, the biotech has launched several more medicines, become the undisputed leader in this field, and delivered excellent stock market returns. However, Vertex Pharmaceuticals is entering a new era with a more diversified portfolio of approved products. And recent developments could enable the company to generate significant sales in the hormone disorder market over the medium term. Here's what investors should know. Image source: The Motley Fool. Continue reading